Eur Heart J:二甲双胍治疗无糖尿病冠心病患者左​​心室肥厚的疗效分析

2019-04-17 xing.T 网络

由此可见,二甲双胍治疗显著降低LVMI、LVM、诊室收缩压、体重和氧化应激。虽然LVH是心血管(CV)结局的良好替代指标,但是需要大型CV结局试验来确切证明二甲双胍的心脏保护作用。

近日,血管领域权威杂志Eur Heart J上发表了一篇研究文章,研究人员旨在评估二甲双胍可能使患有胰岛素抵抗(IR)和/或糖尿病前期的冠状动脉疾病(CAD)患者左心室肥厚(LVH)逆转的假设。

研究人员随机分配了68例无糖尿病但患有IR和/或糖尿病前期的CAD患者(平均年龄为65±8岁),接受二甲双胍XL(每日剂量2000mg)或安慰剂治疗12个月。该研究的主要终点是通过磁共振成像评估的经身高1.7指数化的左心室质量变化(LVMI)。

在改良的意向治疗分析(n=63)中,与安慰剂组相比,二甲双胍治疗显著降低LVMI(绝对平均差为-1.37(95%置信区间:-2.63至-0.12,P=0.033)。二甲双胍也显著减少其他次要研究终点,如:LVM(P=0.032)、体重(P=0.001)、皮下脂肪组织(P=0.024)、诊室收缩压(P=0.022)和氧化应激的生物标志物硫代巴比妥酸反应物质浓度(P=0.04)。在研究结束时,研究组之间的糖化血红蛋白A1C浓度和空腹IR指数没有差异。

由此可见,二甲双胍治疗显著降低LVMI、LVM、诊室收缩压、体重和氧化应激。虽然LVH是血管(CV)结局的良好替代指标,但是需要大型CV结局试验来确切证明二甲双胍的心脏保护作用。 

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1647238, encodeId=35b5164e2384d, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Fri Jan 10 16:36:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769311, encodeId=77421e6931196, content=<a href='/topic/show?id=ab5a509656a' target=_blank style='color:#2F92EE;'>#心室肥厚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50965, encryptionId=ab5a509656a, topicName=心室肥厚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb5738012707, createdName=wjcjjian, createdTime=Sun Feb 02 21:36:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364900, encodeId=be40364900d4, content=又增加一条二甲双胍的用途,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=QFXL123456, createdTime=Fri Apr 19 13:51:52 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357166, encodeId=57ec135e166dc, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447748, encodeId=372f144e748b7, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563086, encodeId=1de01563086a2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032130, encodeId=d08a103213008, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041452, encodeId=f09d104145276, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042391, encodeId=10f8104239152, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364807, encodeId=980636480ea1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f2c1823547, createdName=ms8675815862301566, createdTime=Wed Apr 17 20:38:10 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1647238, encodeId=35b5164e2384d, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Fri Jan 10 16:36:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769311, encodeId=77421e6931196, content=<a href='/topic/show?id=ab5a509656a' target=_blank style='color:#2F92EE;'>#心室肥厚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50965, encryptionId=ab5a509656a, topicName=心室肥厚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb5738012707, createdName=wjcjjian, createdTime=Sun Feb 02 21:36:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364900, encodeId=be40364900d4, content=又增加一条二甲双胍的用途,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=QFXL123456, createdTime=Fri Apr 19 13:51:52 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357166, encodeId=57ec135e166dc, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447748, encodeId=372f144e748b7, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563086, encodeId=1de01563086a2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032130, encodeId=d08a103213008, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041452, encodeId=f09d104145276, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042391, encodeId=10f8104239152, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364807, encodeId=980636480ea1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f2c1823547, createdName=ms8675815862301566, createdTime=Wed Apr 17 20:38:10 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1647238, encodeId=35b5164e2384d, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Fri Jan 10 16:36:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769311, encodeId=77421e6931196, content=<a href='/topic/show?id=ab5a509656a' target=_blank style='color:#2F92EE;'>#心室肥厚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50965, encryptionId=ab5a509656a, topicName=心室肥厚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb5738012707, createdName=wjcjjian, createdTime=Sun Feb 02 21:36:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364900, encodeId=be40364900d4, content=又增加一条二甲双胍的用途,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=QFXL123456, createdTime=Fri Apr 19 13:51:52 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357166, encodeId=57ec135e166dc, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447748, encodeId=372f144e748b7, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563086, encodeId=1de01563086a2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032130, encodeId=d08a103213008, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041452, encodeId=f09d104145276, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042391, encodeId=10f8104239152, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364807, encodeId=980636480ea1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f2c1823547, createdName=ms8675815862301566, createdTime=Wed Apr 17 20:38:10 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2019-04-19 QFXL123456

    又增加一条二甲双胍的用途,学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1647238, encodeId=35b5164e2384d, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Fri Jan 10 16:36:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769311, encodeId=77421e6931196, content=<a href='/topic/show?id=ab5a509656a' target=_blank style='color:#2F92EE;'>#心室肥厚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50965, encryptionId=ab5a509656a, topicName=心室肥厚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb5738012707, createdName=wjcjjian, createdTime=Sun Feb 02 21:36:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364900, encodeId=be40364900d4, content=又增加一条二甲双胍的用途,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=QFXL123456, createdTime=Fri Apr 19 13:51:52 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357166, encodeId=57ec135e166dc, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447748, encodeId=372f144e748b7, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563086, encodeId=1de01563086a2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032130, encodeId=d08a103213008, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041452, encodeId=f09d104145276, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042391, encodeId=10f8104239152, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364807, encodeId=980636480ea1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f2c1823547, createdName=ms8675815862301566, createdTime=Wed Apr 17 20:38:10 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2019-04-19 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1647238, encodeId=35b5164e2384d, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Fri Jan 10 16:36:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769311, encodeId=77421e6931196, content=<a href='/topic/show?id=ab5a509656a' target=_blank style='color:#2F92EE;'>#心室肥厚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50965, encryptionId=ab5a509656a, topicName=心室肥厚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb5738012707, createdName=wjcjjian, createdTime=Sun Feb 02 21:36:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364900, encodeId=be40364900d4, content=又增加一条二甲双胍的用途,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=QFXL123456, createdTime=Fri Apr 19 13:51:52 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357166, encodeId=57ec135e166dc, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447748, encodeId=372f144e748b7, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563086, encodeId=1de01563086a2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032130, encodeId=d08a103213008, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041452, encodeId=f09d104145276, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042391, encodeId=10f8104239152, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364807, encodeId=980636480ea1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f2c1823547, createdName=ms8675815862301566, createdTime=Wed Apr 17 20:38:10 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1647238, encodeId=35b5164e2384d, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Fri Jan 10 16:36:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769311, encodeId=77421e6931196, content=<a href='/topic/show?id=ab5a509656a' target=_blank style='color:#2F92EE;'>#心室肥厚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50965, encryptionId=ab5a509656a, topicName=心室肥厚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb5738012707, createdName=wjcjjian, createdTime=Sun Feb 02 21:36:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364900, encodeId=be40364900d4, content=又增加一条二甲双胍的用途,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=QFXL123456, createdTime=Fri Apr 19 13:51:52 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357166, encodeId=57ec135e166dc, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447748, encodeId=372f144e748b7, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563086, encodeId=1de01563086a2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032130, encodeId=d08a103213008, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041452, encodeId=f09d104145276, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042391, encodeId=10f8104239152, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364807, encodeId=980636480ea1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f2c1823547, createdName=ms8675815862301566, createdTime=Wed Apr 17 20:38:10 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2019-04-19 slcumt
  7. [GetPortalCommentsPageByObjectIdResponse(id=1647238, encodeId=35b5164e2384d, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Fri Jan 10 16:36:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769311, encodeId=77421e6931196, content=<a href='/topic/show?id=ab5a509656a' target=_blank style='color:#2F92EE;'>#心室肥厚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50965, encryptionId=ab5a509656a, topicName=心室肥厚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb5738012707, createdName=wjcjjian, createdTime=Sun Feb 02 21:36:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364900, encodeId=be40364900d4, content=又增加一条二甲双胍的用途,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=QFXL123456, createdTime=Fri Apr 19 13:51:52 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357166, encodeId=57ec135e166dc, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447748, encodeId=372f144e748b7, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563086, encodeId=1de01563086a2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032130, encodeId=d08a103213008, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041452, encodeId=f09d104145276, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042391, encodeId=10f8104239152, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364807, encodeId=980636480ea1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f2c1823547, createdName=ms8675815862301566, createdTime=Wed Apr 17 20:38:10 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2019-04-17 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1647238, encodeId=35b5164e2384d, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Fri Jan 10 16:36:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769311, encodeId=77421e6931196, content=<a href='/topic/show?id=ab5a509656a' target=_blank style='color:#2F92EE;'>#心室肥厚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50965, encryptionId=ab5a509656a, topicName=心室肥厚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb5738012707, createdName=wjcjjian, createdTime=Sun Feb 02 21:36:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364900, encodeId=be40364900d4, content=又增加一条二甲双胍的用途,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=QFXL123456, createdTime=Fri Apr 19 13:51:52 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357166, encodeId=57ec135e166dc, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447748, encodeId=372f144e748b7, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563086, encodeId=1de01563086a2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032130, encodeId=d08a103213008, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041452, encodeId=f09d104145276, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042391, encodeId=10f8104239152, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364807, encodeId=980636480ea1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f2c1823547, createdName=ms8675815862301566, createdTime=Wed Apr 17 20:38:10 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2019-04-17 misszhang

    二甲双胍,神药!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1647238, encodeId=35b5164e2384d, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Fri Jan 10 16:36:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769311, encodeId=77421e6931196, content=<a href='/topic/show?id=ab5a509656a' target=_blank style='color:#2F92EE;'>#心室肥厚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50965, encryptionId=ab5a509656a, topicName=心室肥厚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb5738012707, createdName=wjcjjian, createdTime=Sun Feb 02 21:36:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364900, encodeId=be40364900d4, content=又增加一条二甲双胍的用途,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=QFXL123456, createdTime=Fri Apr 19 13:51:52 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357166, encodeId=57ec135e166dc, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447748, encodeId=372f144e748b7, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563086, encodeId=1de01563086a2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032130, encodeId=d08a103213008, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041452, encodeId=f09d104145276, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042391, encodeId=10f8104239152, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364807, encodeId=980636480ea1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f2c1823547, createdName=ms8675815862301566, createdTime=Wed Apr 17 20:38:10 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2019-04-17 misszhang

    谢谢MedSci提供最新的资讯

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1647238, encodeId=35b5164e2384d, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Fri Jan 10 16:36:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769311, encodeId=77421e6931196, content=<a href='/topic/show?id=ab5a509656a' target=_blank style='color:#2F92EE;'>#心室肥厚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50965, encryptionId=ab5a509656a, topicName=心室肥厚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb5738012707, createdName=wjcjjian, createdTime=Sun Feb 02 21:36:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364900, encodeId=be40364900d4, content=又增加一条二甲双胍的用途,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=QFXL123456, createdTime=Fri Apr 19 13:51:52 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357166, encodeId=57ec135e166dc, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447748, encodeId=372f144e748b7, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563086, encodeId=1de01563086a2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Apr 19 11:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032130, encodeId=d08a103213008, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041452, encodeId=f09d104145276, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042391, encodeId=10f8104239152, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 23:36:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364807, encodeId=980636480ea1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f2c1823547, createdName=ms8675815862301566, createdTime=Wed Apr 17 20:38:10 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2019-04-17 ms8675815862301566

    学习了

    0

相关资讯

Radiology :做FDG PET/CT前糖尿病患者停用二甲双胍与否会影响肠道摄取FDG吗?

本研究旨在评价停药二甲双胍24-和48-小时与PET/CT中胃肠道摄取氟18-氟脱氧葡萄糖(FDG)的相关性。

Nature:二甲双胍狙击“最毒”乳腺癌!科学家首次发现,二甲双胍和血红素可抑制三阴乳腺癌肿瘤生长

过去一年,二甲双胍给我们带来了太多的惊喜,降糖、抗癌、解除免疫抑制,以及让人送上膝盖的“抗雾霾”。

7 大要点解读:2018 版二甲双胍临床应用专家共识

二甲双胍临床应用专家共识由母义明、纪立农等内分泌临床专家、药学专家共同制定,以指导临床医生和患者正确认识并合理使用二甲双胍。目前有 2014 年版、2016 年版、2018 年版。二甲双胍临床应用专家共识(2018 年版)从二甲双胍的临床地位与使用时机、作用机制、剂量与临床疗效、特殊人群用药、安全性、对心血管系统的影响、其他作用七个方面分别进行了阐述。与 2016 年版共识相比,主要是纳入近两

Heart:二甲双胍与主动脉瘤

根据现有的流行病学证据,二甲双胍处方可以限制主动脉瘤患者的瘤体扩张,并可能降低主动脉瘤和主动脉瘤事件的发生率。需要随机对照试验来确认二甲双胍是否可以减少糖尿病患者或不患糖尿病患者的AAA扩大。

JCEM:高血糖和服用二甲双胍与老年人B族维生素缺乏和认知功能障碍有关

由此可见,二甲双胍在老年人中的使用与较差的认知表现有关;可能涉及B族维生素缺乏症。强化食品可以优化B族维生素的状态,可能有助于维持糖尿病患者或糖尿病风险的老年人更好的认知健康。